Global Neurodegenerative Diseases Drugs Market 2018-2023 - MS Set to Dominate with Tecfidera and Ocrevus - ResearchAndMarkets.com

DUBLIN--()--The "Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer's Disease and SMA Show Clinical and Commercial Potential" report has been added to ResearchAndMarkets.com's offering.

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies.

Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities.

It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse and exhibit specific pathophysiologies and etiologies, while affecting people of all ages.

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the five most prevalent neurodegenerative disorders: Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD).

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates.

MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic and has a lucrative pharmacological market following breakthrough success in the past decade. Recent approvals for Ocrevus and Tecfidera are expected to sustain the market in the near future.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2023

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

Companies Mentioned

  • AveXis
  • Biogen
  • Celgene
  • Daiichi
  • Eisai
  • F. Hoffmann-La Roche Ltd.
  • Forest
  • Lundbeck
  • Merz
  • Mitsubishi Tanabe Pharma Corp
  • Novartis
  • Pfizer
  • Reata Pharmaceuticals
  • Sage Therapeutics
  • Sankyo
  • Teva
  • UCB
  • Valeant Pharmaceuticals International Inc.
  • vTv Therapeutics

For more information about this report visit https://www.researchandmarkets.com/research/g2txx9/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Alzheimer's Disease Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs, Alzheimer's Disease Drugs